Pulmonx Corp
NASDAQ:LUNG

Watchlist Manager
Pulmonx Corp Logo
Pulmonx Corp
NASDAQ:LUNG
Watchlist
Price: 1.875 USD -1.83% Market Closed
Market Cap: $77.3m

Operating Margin

-62.4%
Current
Improving
by 20%
vs 3-y average of -82.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-62.4%
=
Operating Income
$-57.2m
/
Revenue
$91.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-62.4%
=
Operating Income
$-57.2m
/
Revenue
$91.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Pulmonx Corp
NASDAQ:LUNG
78.8m USD
Loading...
JP
Hoya Corp
TSE:7741
8.7T JPY
Loading...
CH
Alcon AG
SIX:ALC
31.5B CHF
Loading...
US
Medline Inc
NASDAQ:MDLN
37.3B USD
Loading...
DK
Coloplast A/S
CSE:COLO B
122.5B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
12.1B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
4.8B GBP
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
44B CNY
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
6B USD
Loading...
CH
Ypsomed Holding AG
SIX:YPSN
4.6B CHF
Loading...
KR
HLB Inc
KOSDAQ:028300
7.5T KRW
Loading...

Market Distribution

Lower than 83% of companies in the United States of America
Percentile
17th
Based on 14 112 companies
17th percentile
-62.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Pulmonx Corp
Glance View

Market Cap
77.3m USD
Industry
Health Care

Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

LUNG Intrinsic Value
6.611 USD
Undervaluation 72%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-62.4%
=
Operating Income
$-57.2m
/
Revenue
$91.7m
What is Pulmonx Corp's current Operating Margin?

The current Operating Margin for Pulmonx Corp is -62.4%, which is above its 3-year median of -82.4%.

How has Operating Margin changed over time?

Over the last 3 years, Pulmonx Corp’s Operating Margin has increased from -108.5% to -62.4%. During this period, it reached a low of -109.3% on Dec 31, 2022 and a high of -62.4% on Sep 30, 2025.

Back to Top